What Each Compound Brings

GLP-3 is a single-molecule triple agonist engineered to activate three metabolic receptors at once: GLP-1, GIP, and the glucagon receptor. Where earlier compounds in the class work through one or two incretin pathways, GLP-3 adds glucagon receptor activity, which is associated in the research with increased energy expenditure on top of the intake-side signaling of GLP-1 and GIP. It has become the flagship compound of current metabolic peptide research and is the lead half of this blend by both role and amount. It is not FDA approved.

Eloralintide is a long-acting amylin receptor agonist, and its defining feature is selectivity. Native amylin is the pancreatic hormone co-secreted with insulin, and earlier long-acting analogs built on it activate the calcitonin receptor nearly as strongly as the amylin receptors themselves. Eloralintide was engineered the other way: it preferentially activates the amylin receptors while maintaining selectivity against the calcitonin receptor. Preclinical research associates that cleaner amylin targeting with reduced food intake and body weight effects driven primarily by fat mass, and it is the reason eloralintide is treated as the next step in the amylin class. Its research base sits in the low single-digit milligram range, which is exactly where this blend keeps it. It is not FDA approved.

What's in the Vial

One lyophilized 12.5mg vial containing 10mg GLP-3 and 2.5mg eloralintide, pre-blended at a 4:1 ratio. Tested for purity by third-party HPLC analysis, with the COA available on this product page.

Why Eloralintide

The amylin class has moved. The first generation of long-acting amylin analogs proved the pathway matters, but those compounds carry meaningful activity at the calcitonin receptor alongside the amylin receptors, so the amylin signal comes packaged with off-target signaling. Eloralintide was built to separate the two. It is engineered to activate the amylin receptors with selectivity over the calcitonin receptor, giving researchers a more precise tool for isolating amylin pathway effects. Pairing that selective amylin layer with GLP-3's triple incretin agonism puts the most advanced compound from each class into one vial, and you will only find this formulation at PeptidePlugs.

The PeptidePlugs Blend Standard

Custom blends are what we are known for. While most of the market resells the same stock formulations, PeptidePlugs designs its own, and every one of them starts from the same question: what does the research on each compound actually support? That discipline produced our ratio-correct GLP-3 + Cagrilintide blend, the KLOW Pro recovery formulation, and now this pairing. GLP-3 + Eloralintide is a first-to-market formulation. Eloralintide is the newest compound in the amylin class, and we are the first to pair it with GLP-3 in a pre-mixed, ratio-correct vial. When the amylin class moved forward, so did we.

Why This Ratio

The same ratio discipline that defines our GLP-3 + Cagrilintide blend applies here. The common mistake in market blends is scaling the amylin compound milligram for milligram alongside the lead peptide, which balloons it far past anything its own literature supports. This blend is built compound by compound instead. GLP-3 sits at 10mg, the forward end of its research range, while eloralintide is held at 2.5mg, squarely inside the low single-digit range where the amylin agonist is actually characterized. The result is a 4:1 ratio in which eloralintide does its job as a second suppression layer without being inflated into a co-lead it was never studied to be.

Research Context

GLP-3 is among the most closely watched compounds in metabolic research, with a rapidly growing body of literature on triple receptor agonism. Eloralintide is newer still, and interest in selective amylin receptor agonism is expanding quickly, both as a standalone research direction and in combination with incretin-class compounds. Neither compound is FDA approved, and no published data exists on this specific two-peptide formulation at this ratio. Researchers using this blend are working ahead of the formal evidence base on the combination itself, even though each individual peptide carries an active and growing literature.

Stacking Notes

This blend is designed to be a complete two-axis suppression stack on its own, which is the reason for the pre-mixed format. Researchers extending their metabolic work sometimes run it alongside compounds from other categories entirely, such as repair or GH-axis peptides, rather than adding further incretin-class material. No published data exists on this blend combined with other compounds.

Storage

Store the lyophilized product refrigerated and away from light. Keep sealed and protected from moisture until use. Do not freeze.